Accelovance completes THERAMetrics integration, boosts early cancer offering

Cancer and vax niche CRO Accelovance has after 5 months merged THERAMetrics’ three CRO subsidiaries and a Phase I unit in Germany, Italy and Romania into its company.

The money side of things has still not been made public, but the company said its investment “further enhances its early phase oncology services,” as well as its European footprint.

The Rockville, MD-based CRO the merging of THERAMetrics’ European staff will allow it a “step‐wise approach” in trials with joint U.S. and EU involvement.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

“These integrated services support our existing strategic approaches to better serve early phase oncology clients through our scientific and regulatory expertise, our strategic site and network relationships, and the therapeutic expertise of our team members,” Accelovance explained.

Steve Trevisan, Accelovance CEO, added: “Early phase oncology support and focus remains underserved by most CROs, and sponsors are actively looking for CRO partners like Accelovance that offer tangible differentiators and, most importantly, are able to exceptionally execute these trials in the most expeditious, cost sensitive way while ensuring patient safety.

“We will continue to invest in oncology-dedicated staff, expand our strategic site and network relationships, and continuously assess our technology and processes to ensure we effectively execute and provide value to our sponsors.”

The acquisition adds to Accelovance's European and service expansion efforts over the last two years with its buys of providers Altair Clinical, from the U.K., and Amsterdam’s Clinquest.

The CRO, long specializing in oncology and vaccine development, expanded into general medicine in 2013 with its acquisition of Radiant Development, the CRO arm of Radiant Research. That deal gave Accelovance new capabilities in cardiovascular, dermatology, nutrition and urology, plus outposts in Illinois and Florida.

THERAMetrics, a global technology-based contract research and development organization, is listed on the SIX Swiss Exchange under the symbol "TMX" and is headquartered in Stans, Switzerland.


Suggested Articles

CTI Clinical Trial and Consulting Services is buying up fellow CRO Clinart to deepen its reach in the Middle Eastern and Northern African regions.

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.